Diagnosis and treatment of Graves disease

Annals of Pharmacotherapy

Volumn 37, Issue 7-8, 2003, Pages 1100-1109

  Streetman, Darcie D ^a   Khanderia, Ujjaini ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Graves disease; Hyperthyroidism; Inorganic iodide; Lithium; Methimazole; Propylthiouracil; blockers

Indexed keywords

ANTITHYROID AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBIMAZOLE; IODIDE; IODINE 131; IOPANOIC ACID; LITHIUM; POTASSIUM IODIDE; PROPRANOLOL; PROPYLTHIOURACIL; RADIOACTIVE IODINE; THIAMAZOLE; THYROID HORMONE;

AGRANULOCYTOSIS; ARTHRALGIA; CLINICAL FEATURE; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; EYE DISEASE; FEVER; GRAVES DISEASE; HEPATITIS; HORMONE SYNTHESIS; HUMAN; HYPERTHYROIDISM; LABORATORY DIAGNOSIS; LUPUS LIKE SYNDROME; LUPUS VULGARIS; MEDLINE; PATHOGENESIS; PRIORITY JOURNAL; RASH; REVIEW; SKIN DISEASE; THYROID SURGERY; URTICARIA;

EID: 0037765104     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C299     Document Type: Review

References (71)

1. LoPresti JS, Singer PA. Physiology of thyroid hormone synthesis, secretion, and transport. In: Falk SA, ed. Thyroid disease: endocrinology, surgery, nuclear medicine, and radiotherapy. 2nd ed. Philadelphia: Lippincott-Raven, 1997:29-40.
2. Reed L, Pangaro LN. Physiology of the thyroid gland I: synthesis and release, iodine metabolism, and binding and transport. In: Becker KL, ed. Principles and practice of endocrinology and metabolism. 2nd ed. Philadelphia: JB Lippincott, 1995:285-91.
3. Burman KD. Hyperthyroidism. In: Becker KL, ed. Principles and practice of endocrinology and metabolism. 2nd ed. Philadelphia: JB Lippincott, 1995:367-85.
4. O'Donnell AL, Spaulding SW. Hyperthyroidism: systemic effects and differential diagnosis. In: Falk S, ed. Thyroid disease: endocrinology, surgery, nuclear medicine, and radiotherap. 2nd ed. Philadelphia: Lippincott-Raven, 1997:241-51.
5. Ladenson PW. Diagnosis of thyrotoxicosis. In: Braverman LE, Utiger RD, eds. Werner and Ingbar's the thyroid. 7th ed. Philadelphia: Lippincott-Raven, 1996:708-11.
6. Khanderia U, Khanderia VS. Effect of the thyroid on different organ systems. US Pharmacist 1999;24:85-94.
7. Dabon-Almirante CL, Surks MI. Clinical and laboratory diagnosis of thyrotoxicosis. Endocrinol Metab Clin North Am 1998;27:25-35.
8. Burch HB, Wartofsky L. Graves ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 1993;14:747-93.
9. Weetman AP. Thyroid-associated ophthalmopathy. Autoimmunity 1992;12:215-22.
10. Wiersinga WM. Immunosuppressive treatment of Graves ophthalmopathy. Thyroid 1992;2:229-33.
11. Lang PG, Sisson JC, Lynch PJ. Intralesional triamcinolone therapy for pretibial myxedema. Arch Dermatol 1975;111:197-202.
12. Parker LN, Wu S-Y, Lai MK, Ramadan MB, Rajan RK, Yusi AM. The early diagnosis of atypical thyroid acropachy. Arch Intern Med 1982;142:1749-51.
13. Ladenson PW, Singer PA, Ain KB, Bagchi N, Bigos ST, Levy EG, et al. American Thyroid Association guidelines for detection of thyroid dysfunction. Arch Intern Med 2000;160:1573-5.
14. Davies PH, Franklyn JA. The effects of drugs on tests of thyroid function. Eur J Clin Pharmacol 1991;40:439-51.
15. Arafah BM. Increased need for thyroxine in women with hypothyroidism during estrogen therapy. N Engl J Med 2001;344:1743-9.
16. McDougall IR, Maclin N. Hypothyroid women need more thyroxine when pregnant. J Fam Pract 1995;41:238-40.
17. Chopra IJ. Euthyroid sick syndrome: is it a misnomer? J Clin Endocrinol Metab 1997;82:329-34.
18. Feldt-Rasmussen U, Schleusener H, Carayon P. Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease. J Clin Endocrinol Metab 1994;78:98-102.
19. Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, et al. Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid 1991;1:129-35.
20. Solomon B, Glinoer D, Lagasse R, Wartofsky L. Current trends in the management of Graves disease. J Clin Endocrinol Metab 1990;70:1518-24.
21. Jansson R, Dahlberg PA, Lindstrom B. Comparative bioavailability of carbimazole and methimazole. J Clin Pharm Ther Toxicol 1983;21:505-10.
22. Cooper DS, Saxe VC, Meskell M, Maloof F, Ridgway EC. Acute effects of propylthiouracil (PTU) on thyroidal iodine organification and peripheral iodothyronine deiodination: correlation with serum PTU levels measured by radioimmunoassay. J Clin Endocrinol Metab 1982;54:101-7.
23. Jansson R, Lindstrom B, Dahlberg PA. Pharmacokinetic properties and bioavailability of methimazole. Clin Pharmacokinet 1985;10:443-50.
24. Jansson R, Dahlberg PA, Johansson H, Lindstrom B. Intrathyroidal concentrations of methimazole in patients with Graves' disease. J Clin Endocrinol Metab 1983;57:129-32.
25. Low LCK, McCruden DC, Alexander WD. Intrathyroidal iodide binding rates and plasma methimazole concentrations in hyperthyroid patients on small doses of carbimazole. Br J Clin Pharmacol 1981;12:315-8.
26. Barnes HV, Bledsoe T. A simple test for selecting the thioamide schedule in thyrotoxicosis. J Clin Endocrinol Metab 1972;35:250-5.
27. Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Endocrinol Metab Clin North Am 1993;22:263-77.
28. Nicoloff JT. Thyroid storm and myxedema coma. Med Clin North Am 1985;69:1005-17.
29. Cooper DS, Bode HH, Nath B, Saxe V, Maloof F, Ridgway EC. Methimazole pharmacology in man: studies using a newly developed radioimmunoassay for methimazole. J Clin Endocrinol Metab 1984;58:473-9.
30. Marchant B, Brownlie BEW, Hart DM, Horton PW, Alexander WD. The placental transfer of propylthiouracil, methimazole, and carbimazole. J Clin Endocrinol Metab 1977;45:1187-93.
31. Kampmann JP, Hansen JM. Serum protein binding of propylthiouracil. Br J Clin Pharmacol 1983;16:549-52.
32. Kampmann JP, Hansen JM, Johansen K, Helweg J. Propylthiouracil in human milk. Lancet 1980;2:736-7.
33. Volpe R. Evidence that the immunosuppressive effects of antithyroid drug are mediated through actions on the thyroid cell, modulating thyrocyte-immunocyte signaling. Thyroid 1994;4:217-23.
34. Cooper DS. Treatment of thyrotoxicosis. In: Braverman LE, Utiger RD, eds. Werner and Ingbar's the thyroid. 7th ed. Philadelphia: Lippincott-Raven, 1996:713-34.
35. Farwell AP, Braverman LE. Thyroid and antithyroid drugs. In: Hardman JG, Limberd LE, eds. Goodman and Gilman's: the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001:1563-96.
36. Tajiri J, Noguchi S, Marakami T, Murakami N. Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring. Arch Intern Med 1990;150:621-4.
37. Vitug AC, Goldman JM. Hepatotoxicity from antithyroid drugs. Horm Res 1985;21:229-34.
38. Wing SS, Fantus IG. Adverse immunologic effects of antithyroid drugs. Can Med Assoc J 1987;136:121-7.
39. Cooper DS. Antithyroid drugs for the treatment of hyperthyroidism caused by Graves' disease. Endocrinol Metab Clin 1998;27:225-47.
40. Wall JR, Fang SL, Kuroki T, Ingbar SH, Braverman LE. In vitro immunoreactivity to propylthiouracil, methimazole, and carbimazole in patients with Graves' disease: a possible cause of antithyroid drug-induced agranulocytosis. J Clin Endocrinol Metab 1984;58:868-72.
41. Tamai H, Mukuta T, Matsubayashi S, Fukata S, Komaki G, Kuma K, et al. Treatment of methimazole-induced agranulocytosis using recombinant human granulocyte colony-stimulating factor (rhG-CSF). J Clin Endocrinol Metab 1993;77:1356-60.
42. Nicholas WC, Fischer RG, Stevenson RA, Bass JD. Single daily dose of methimazole compared to every 8 hours of propylthiouracil in the treatment of hyperthyroidism. South Med J 1995;88:973-6.
43. Benker G, Reinwein D, Kahaly G, Tegler L, Alexander WD, Fassbinder J, et al. Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs. Clin Endocrinol (Oxf) 1998;49:451-7.
44. Romaldini JH, Bromberg J, Werner RS, Tanaka LM, Rodrigues HF, Werner MC, et al. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism. J Clin Endocrinol Metab 1983;57:563-70.
45. Mashio Y, Beniko M, Matsuda A, Koizumi S, Matsuya K, Mizumoto H, et al. Treatment of hyperthyroidism with a small single daily dose of methimazole: a prospective long-term follow-up study. Endocr J 1997;44:553-8.
46. Benker G, Vitti P, Kahaly G, Raue F, Tegler L, Hirche H, et al. Response to methimazole in Graves' disease. Clin Endocrinol (Oxf) 1995;43:257-63.
47. Mortimer RH, Cannell GR, Addison RS, Johnson LP, Roberts KS, Bernus I. Methimazole and propylthiouracil equally cross the perfused human term placenta lobule. J Clin Endocrinol Metab 1997;82:3099-102.
48. Wing DA, Millar LK, Koonings PP, Montoro MN, Mestman JH. A comparison of propylthiouracil versus methimazole in the treatment of hyperthyroidism in pregnancy. Am J Obstet Gynecol 1994;170(1 pt 1):90-5.
49. Shanks RG, Hadden DR, Lowe DC, McDevitt DG, Montgomery DAD. Controlled trial of propranolol in thyrotoxicosis. Lancet 1969;1:993-4.
50. Geffner DL, Hershman J. β-adrenergic blockade for the treatment of hyperthyroidism. Am J Med 1992;93:61-8.
51. Feely J, Isles TE, Ratcliffe WA, Crooks J. Propranolol, triiodothyronine, reverse triiodothyronine and thyroid disease. Clin Endocrinol 1979;10:531-8.
52. Cooper DS, Daniels GH, Ladenson PW, Ridgeway EC. Hyperthyroxinemia in patients treated with high-dose propranolol. Am J Med 1982;73:867-71.
53. Philippou G, Koutras DA, Piperingos G, Souvatzoglou A, Moulopoulos SD. The effect of iodide on serum thyroid hormone levels in normal persons, in hyperthyroid patients, and in hypothyroid patients treated on thyroxine replacement. Clin Endocrinol (Oxf) 1992;36:573-8.
54. Braga M, Cooper DS. Oral cholecystographic agents and the thyroid. J Clin Endocrinol Metab 2001;86:1853-60.
55. Spaulding SW, Burrow GN, Bermudez F, Himmelhoch M. The inhibitory effect of lithium on thyroid hormone release in both euthyroid and thyrotoxic patients. J Clin Endocrinol Metab 1972;35:905-11.
56. Kristensen O, Andersen HH, Pallisgaard G. Lithium carbonate in the treatment of thyrotoxicosis. Lancet 1976;2:603-5.
57. Bogaszzi F, Bartalena L, Campomori A, Brogioni S, Traino C, De Martino F, et al. Treatment with lithium prevents serum thyroid hormone increase after thonamide withdrawal and radioiodine therapy in patients with Graves disease. J Clin Endocrinol Metab 2002;4490-5.
58. Rivkees SA, Sklar C, Freemark M. The management of Graves disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab 1998;83:3767-76.
59. McDougall R. Graves disease: current concepts. Med Clin North Am 1991;75:79-95.
60. Atkinson S, McGregor AM, Kendall-Taylor P, Peterson MM, Smith BR. Effect of radioiodine on stimulatory activity of Graves' immunoglobulins. Clin Endocrinol (Oxf) 1982;16:537-43.
61. Kung WC, Yau CC, Cheng A. The incidence of ophthalmopathy after radioiodine therapy for Graves disease: prognostic factors and the role of methimazole. J Clin Endocrinol Metab 1994;79:542-6.
62. Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med 1992;326:1733-8.
63. Gwinup G, Elias AN, Ascher MS. Effect on exophthalmus of various methods of treatment of Graves disease. JAMA 1982;247:2135-8.
64. Sridama V, DeGroot LJ. Treatment of Graves disease and the course of ophthalmopathy. Am J Med 1989;87:70-3.
65. Holm LE, Dahlqvist I, Israelsson A, Lundell G. Malignant thyroid tumors after iodine-131 therapy: a retrospective cohort study. N Engl J Med 1980;303:188-91.
66. Levy WU, Schumacher OP, Gupta M. Treatment of childhood Graves disease. Cleve Clin J Med 1988;55:373-82.
67. Sabri O, Zimny M, Schulz G, Schreckenberger M, Reinartz P, Willmes K, et al. Success rate of radioiodine therapy in Graves' disease: the influence of thyrostatic medication. J Clin Endocrinol Metab 1999;84:1229-33.
68. Nakazato N, Yoshida K, Mori K, Kiso Y, Sayama N, Tani JI, et al. Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves' disease. Thyroid 1999;9:775-9.
69. Imseis RE, Vanmiddlesworth L, Massie JD, Bush AJ, Vanmiddlesworth NR. Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism. J Clin Endocrinol Metab 1998;83:685-7.
70. AACE Clinical Practice Guidelines for Evaluation and Treatment of Hyperthyroidism and Hypothyroidism.www.aace.com/clin/guides/thyroid_guide.html (accessed 2000 Mar 16).
71. Patwardhan NA, Moront M, Rao S, Rossi S, Braverman L. Surgery still has a role in Graves hyperthyroidism. Surgery 1993;114:1108-13.